The Role of Fecal Calprotectin in Investigating Pediatric Ulcerative Colitis

Yıl 2012, , 80 - 84, 01.12.2012

Fatih Ünal , Evren Semizel Muhittin Serdar Çiğdem Ömür Ecevit Yılmaz Karaca Emine Mert Yılmaz Hasan Kocaefe Hasan Erhun Kasırga

https://doi.org/10.4274/Jcp.10.02

Öz

Introduction: Fecal calprotectin FCP can be found in high concentrations in inflammatory bowel disease due to the increase in leucocyte turnover in intestinal wall or increase of migration of neutrophils into the lumen. In this study, we aimed to determine the FCP values of the ulcerative colitis UC patients at the time of diagnosis and to investigate the applicability and effectiveness of this non-invasive method in the diagnosis of the disease, routinely. Materials and Methods: A total of 19 patients with UC 10 females, 9 males, age: 11.5±3.5 years old whoose stool samples collected during the diagnosis period and 20 healthy controls 10 female, 10 male, age: 10.3±4.5 years old were included in the study. Stool samples were collected for FCP analysis by ELISA method at the time of diagnosis and before the treatment period. Results: FCP values of the UC group were statistically higher than the control group. FCP values of the UC and control groups were 398.4 μg/gr stool 56.7-2450 and 19.4 μg/gr stool 2-81 , respectively p

Anahtar Kelimeler

Ulcerative colitis, fecal calprotectin, inflammatory bowel disease

Çocuklarda Ülseratif Kolit Tanısının Belirlenmesinde Fekal Kalprotektinin Rolü

Öz

Giriş: Dışkıda fekal kalprotektin FKP inflamatuvar bağırsak hastalıklarında İBH , bağırsak duvarındaki lökositlerin döngüsünün ve bağırsak lümeni içerisine nötrofillerin migrasyonunun artmasıyla yüksek konsantrasyonlarda bulunabilmektedir. Çalışmamızda ülseratif kolitli ÜK hastalarımızda tanı anında FKP değerlerini belirlemeyi ve noninvazif bir yöntem olan bu testin rutin uygulanabilirliğinin etkinliği amaçlanmıştır. Gereç ve Yöntem: Çalışmamıza tanı konulduğu sırada dışkı örnekleri alınmış olan 19 ÜK’li 10 kız, 9 erkek, yaş ort: 11,5±3,5 yıl ve 20 sağlıklı kontrol 10 kız, 10 erkek, yaş ort: 10,3±4,5 yıl dahil edildi. Hastalarımızdan tanı konulduktan hemen sonra, tedavi öncesi, dışkı örnekleri ELİSA yöntemi ile FKP çalışılması için toplandı. Bulgular: ÜK grubunun tamamında FKP değerleri kontrol grubundan anlamlı derecede yüksekti. Dışkıda saptamış olduğumuz FKP değerleri ÜK ve kontrol grubumuzda sırasıyla 398,4 56,7-2450 μg/gr dışkı ve 19,4 2-81 μg/gr dışkı olarak bulundu p

Anahtar Kelimeler

Ülseratif kolit, fekal kalprotektin, inflamatuvar bağırsak hastalığı

Kaynakça

• 1. Erbayrak M, Turkay C, Eraslan E, Çetinkaya H, Kasapoğlu B, Bektaş M. The role of fecal calprotectin in investigating inflamatory bowel diseases. Clinics (Sao Paulo) 2009;64:421-5.
• 2. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, et al. Epidemiologic and clinical charecteristics of children with newly diagnosed inflamatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003;143:525-31.
• 3. Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera C, Vera I, McNicholl AG, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
• 4. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America, Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44:653-74.
• 5. Mack DR, Langton C, Markowitz J, LeLeiko N, Griffiths A, Bousvaros A, et al. Laboratory values for children with newly diagnosed inflamatory bowel disease. Pediatrics 2007;119: 1113-9.
• 6. Uslu N, Baysoy G, Balamtekin N, Hızal G, Demir H, SaltıkTemizel İN, ve ark. Çocuklarda enflamatuar bağırsak hastalığı tanısında noninvasif bir belirteç: fekal kalprotektin. Çocuk Sağlığı ve Hastalıkları Dergisi 2011;54:22-7.
• 7. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful magic or unnecessary toys. Gut 2006;55:426-31.
• 8. Fagerhol MK, Dale I, Andersson T. Release and quantitation of a lycocyte derived protein (L1). Scand J Heamatol 1980;24:393-8.
• 9. Ertekin V, Selimoğlu MA, Turgut A, Bakan N. Fecal calprotectin concetrationin celiac disease. J Clin Gastroenterol 2010;44:544-6.
• 10. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Cinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-6.
• 11. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6.
• 12. Carroccio A, Iacono G, Cottone M, Prima LD, Cartabellotta F, Cavataio F, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861-7.
• 13. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflamation and damage. Gut 2009;58:859-68.
• 14. Kolho KL, Raivo T, Lindahl H, savilahti E. Fecal calprotectin remains high during glucorticoid theraphy in children inflamatory bowel disease. Scand J Gastroenterol 2006;41:720-5.
• 15. Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflamation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pedatir Gastroenterol Nutr 2005;40:450-5.
• 16. Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, et al. Feacal calprotectin as reliable non-invazive marker to accesi the severety of mukozal inflamation in children with inflamatory bowel disease. Dig Liver Dis 2008;40:547-53.
• 17. Quail MA, Russell RK, Van Limbergen JE, Rogers P, Drummond HE, Wilson DC, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflamatory bowel disease. Inflam Bowel Dis 2009;15:756-9.
• 18. Mack DR, Langton C, Markowitz J, LeLeiko N, Griffiths A, Bousvaros A, et al. Laboratory values for children with newly diagnosed inflamatory bowel disease. Pediatrics 2007;119:1113-9.
• 19. Canani RB, Horatio LT, Terrin G, Romano MT, Miele E, Staiano A, et al. Combined use of noninvasive tests useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;42:9-15.
• 20. Beattie RM, Walker-Smith JA, Murch SH. Indications for invastigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73:354-5.